Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
190 participants
INTERVENTIONAL
2018-01-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Progesterone in Threatened Abortion
NCT02950935
Vaginal Progesterone for Treatment of Threatened Miscarriage
NCT02690129
Oral Progesterone for Prevention of Miscarriage in Threatened Abortion
NCT04788108
Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage
NCT01670929
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
NCT03680339
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Progesterone
received rectal progesterone suppositories 400 mg once daily
Progesterone
received rectal progesterone suppositories 400 mg once daily
Control group
received placebo suppositories rectally once daily.
Placebos
received placebo suppositories rectally once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Progesterone
received rectal progesterone suppositories 400 mg once daily
Placebos
received placebo suppositories rectally once daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* singleton
* viable fetus
* gestational age \< 20 weeks
* closed normal length cervix.
Exclusion Criteria
* dead fetus
* open cervix ≥ 2cm
* history of cervical surgery
* refusal to participate.
20 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ayman S Dawood, MD
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ayman Shehata Dawood
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Prog133077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.